TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03671018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (IV)
Description: Participants will receive intravenous (IV) mosunetuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (IV)
Description: Participants will receive intravenous (IV) mosunetuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (IV)
Description: Participants will receive intravenous (IV) mosunetuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (SC)
Description: Participants will receive subcutaneous (SC) mosunetuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (SC)
Description: Participants will receive subcutaneous (SC) mosunetuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Participants will receive IV polatuzumab vedotin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Participants will receive IV polatuzumab vedotin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Participants will receive IV polatuzumab vedotin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Participants will receive IV polatuzumab vedotin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Participants will receive IV polatuzumab vedotin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive IV rituximab.
Study: NCT01443312

Intervention type: GENETIC
Intervention: Laboratory analysis.
Description: The blood transfusions given to the patients are in accord to physician decision and not related to the study
Study: NCT03173378

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will have to complete questionnaires to compare the distribution of occupational situations in narcoleptic patients and matched non-narcoleptic subjects (controls)

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will have to complete questionnaires to compare the distribution of occupational situations in narcoleptic patients and matched non-narcoleptic subjects (controls)
Study: NCT01930708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Administered as per the approved dosage in all countries where DMF has received marketing authorization.
Study: NCT03448653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colonoscopy with NBI
Description: Colonoscopy with NBI
Study: NCT03350620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVK-002 Concentration 1
Description: Study medication will be administered, once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVK-002 Concentration 2
Description: Study medication will be administered, once daily (QD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle (placebo) will be administered, once daily (QD)
Study: NCT03773965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.
Study: NCT03051854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction Competencies with children - for teachers
Description: Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
Study: NCT03875235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
Study: NCT01821170

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological tests
Description: neuropsychological tests will assess attentional and executive performance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological tests
Description: neuropsychological tests will assess attentional and executive performance
Study: NCT02897973

Intervention type: OTHER
Intervention: Activity of daily living
Description: walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending

Intervention type: OTHER
Intervention: Activity of daily living
Description: walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending

Intervention type: OTHER
Intervention: Activity of daily living
Description: walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending
Study: NCT03763643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m2 intravenous on day 0 or -1 prior to kidney transplant

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Plasmapheresis
Description: 1.5 volume exchange plasmapheresis with fresh frozen plasma replacement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: 1.5 volume exchange plasmapheresis with fresh frozen plasma replacement
Study: NCT05966909

Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler Ultrasound
Description: Ultrasound diagnosi of asymptomatic and symptomatic upper extremities vein thrombosis
Study: NCT01467362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0034CR01B
Description: Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desonide 0.1% cream
Description: cream, once a day (in the evening) during flares

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: desonide 0.1% cream
Description: cream, once a day (in the evening) during flares

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foaming gel
Description: for the washing and cleaning

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Foaming gel
Description: for the washing and cleaning
Study: NCT03316976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole delayed-release capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole delayed-release capsule.
Study: NCT02172469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation powder capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Metered Dose Inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium Bromide Metered Dose Inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo inhalation powder capsule
Study: NCT00683592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilazodone
Description: titration to 40 mg tablets qd (once a day) for 8 weeks
Study: NCT02661815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Please see arm/group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Please see arm/group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Please see arm/group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Please see arm/group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ricolinostat
Description: Please see arm/group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ricolinostat
Description: Please see arm/group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ricolinostat
Description: Please see arm/group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ricolinostat
Description: Please see arm/group description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Please see arm/group description.
Study: NCT02557919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Training
Description: 1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Best Practice
Description: .5 day training on tobacco control and emerging products.
Study: NCT02103179

Intervention type: PROCEDURE
Intervention: surgical treatment
Description: all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
Study: NCT01443026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene 30mg
Description: Lycopene 30 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01390103

Intervention type: OTHER
Intervention: Assessment following hip injection
Description: Assessment to evaluate the effect of the hip injection on biomechanics.
Study: NCT04386057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle
Study: NCT03541603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: A sterile 2.5mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
Study: NCT04386057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: LY3214996-daily oral dosage per protocol per 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: LY3214996-daily oral dosage per protocol per 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: LY3214996-daily oral dosage per protocol per 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3214996
Description: LY3214996-daily oral dosage per protocol per 28 day cycle
Study: NCT02637622

Intervention type: OTHER
Intervention: Best-Worst Scaling (Case 2)
Description: Respondents receive questions asking them to choose the best and worst features of a hypothetical medication.

Intervention type: OTHER
Intervention: Discrete Choice Experiment
Description: Respondents receive questions asking them to choose the medication they prefer between a pair of hypothetical medications.
Study: NCT04411069

Intervention type: DRUG
Group type: OTHER
Intervention: Droperidol
Description: Pacients who had nausea and vomiting induced by chemotherapy will receive three anti emetic drugs: 4mg dexametasone, 4 mg ondansetron and 0,625 mg droperidol
Study: NCT02005926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wire-localized abnormal node
Description: Before the sentinel lymph node biopsy (SLNB) operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance to localize the abnormal node. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
Study: NCT02393625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib (LDK378)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib (LDK378)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT00721110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo boluses and infusions will be substituted

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine + Lidocaine
Description: both Ketamine and Lidocaine will be given
Study: NCT00529815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucometer
Description: The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
Study: NCT00854737

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cytidine
Description: cytidine (2g po daily for 4 months)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids
Description: omega-3 fatty acids (4g po daily for 4 months)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids
Description: omega-3 fatty acids (4g po daily for 4 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill
Study: NCT03190954

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [11C]raclopride plus placebo
Description: Placebo (po) will be given 60 minutes prior to \[11C\]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C]raclopride plus drug
Description: Methylphenidate 60 mg. po will be given 60 minutes prior to \[11C\]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [11C]NNC-112
Description: \[11C\]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C]NNC-112
Description: \[11C\]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: [11C]NNC-112
Description: \[11C\]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
Study: NCT05116644

Intervention type: OTHER
Intervention: NONE - this is a cross-sectional survey design
Description: NONE - this is a cross-sectional survey design
Study: NCT01586897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Metronome
Description: Providers allocated to intervention will see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT01251757

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Voice Recognition (IVR) phone calls
Description: The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and tardy calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Voice Recognition (IVR) phone calls
Description: The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and tardy calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational mailings and follow-up for nonadherence
Description: Participants received bimonthly educational materials by mail. In addition, patients received mailed refill reminder letters and their providers were notified electronically if the patients failed to refill in response to the automated calls. The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as frequently asked questions (FAQs) about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.
Study: NCT03686189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iliac Bifurcation Stent Graft System
Description: Device placement after preoperative preparation. For patients with the aortoiliac aneurysm, the placement of short-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft, or the placement of long-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft are recommended.
Study: NCT03539640

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP: 5 cmH2O
Description: During second part of the study (MRI)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP: 10 cmH2O
Description: During second part of the study (MRI)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP: 15 cmH2O
Description: During second part of the study (MRI)
Study: NCT04642079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: 20-valent pneumococcal conjugate vaccine
Study: NCT03191331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Written material on healthy diet during pregnancy, dietary counseling at each maternity clinic visit given by public health nurse, group meeting with a dietician x2.
Study: NCT03487458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rib Fixation Surgery
Description: Rib Fixation Surgery
Study: NCT01414790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADM
Description: 29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
Study: NCT03721367

Intervention type: OTHER
Intervention: Diagnostic Ultrasound
Description: All individuals will undergo a blood draw for measurement of biomarkers of liver disease and an ultrasound with shear-wave elastography.
Study: NCT02298946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-224
Description: 10mg/kg on day 1 then every 14 days for a total of 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-224
Description: 10mg/kg on day 1 then every 14 days for a total of 6 doses.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy(SBRT)
Description: Dose Level 1: 8Gy x 1 day. Dose Level 2: 8Gy x 3 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy(SBRT)
Description: Dose Level 1: 8Gy x 1 day. Dose Level 2: 8Gy x 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 200mg/m(2) IV on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 200mg/m(2) IV on day 0.